4basebio Plc - Directors' Dealings
05 Febrero 2024 - 1:00AM
UK Regulatory
4basebio Plc - Directors' Dealings
PR Newswire
LONDON, United Kingdom, February 05
5
February 2024
4basebio
plc
(“4babsebio” or
the "Company")
Directors’
Dealings
Cambridge, UK, 5
February 2024 - 4basebio PLC (AIM: 4BB), an innovation
driven biotechnology company enabling and accelerating development
of advanced therapy medicinal products (ATMPs) through its high
performant synthetic DNA products and non-viral, thermostable
nucleic acid delivery platform, announces that, further to its
announcement of 2 February 2024,
directors of the Company have sold shares in order to pay for
options exercised as follows:
|
Name |
Number of Shares
Sold |
Sale price per share
(p) |
Shareholding Following
Sale |
Shareholding as a
Percentage of Issued Share
Capital |
|
Heikki
Lanckriet |
45,322 |
660p |
1,418,994 |
11.09% |
|
David
Roth |
38,292 |
660p |
457,708 |
3.58% |
The calculations above are
based on an issued share capital of the Company of 12,796,208 ordinary
shares.
This announcement contains inside information for the
purposes of Article 7 of EU Regulation 596/2014 as amended by
regulation 11 of the market abuse (amendment) (EU Exit) regulations
2019/310.
For further enquiries,
please contact:
|
4basebio
PLC |
+44 (0)12 2396
7943 |
|
Heikki
Lanckriet, CEO |
|
|
|
|
Cairn
Financial Advisers LLP (Nominated
Adviser) |
+44 (0)20 7213
0880 |
|
Jo Turner /
Sandy Jamieson |
|
|
|
|
Cavendish Capital
Markets Limited
(Broker) |
+44 (0)20 7220
0500 |
|
Geoff
Nash/Charlie Beeson |
|
|
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No.
596/2014 |
|
1 |
Details of the person discharging managerial
responsibilities/person closely
associated |
|
a. |
Name |
-
Dr Heikki
Lanckriet
-
David
Roth
|
|
2 |
Reason for
notification |
|
|
a. |
Position/Status |
-
CEO
-
CFO
|
|
b. |
Initial
notification/Amendment |
Initial
Notification |
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
|
a. |
Name |
4basebio
plc |
|
b. |
LEI |
213800E2DX9EAIUNCB30 |
|
4 |
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have been
conducted |
|
a. |
Description of the financial instrument, type of
instrument
Identification Code |
Ordinary
Shares
ISIN:
GB00BMCLYF79 |
|
b. |
Nature of the
transaction |
Sale of Ordinary
Shares |
|
|
|
|
Price(s) per share
(p) |
Volume(s) |
|
-
660p
-
660p
|
45,322
38,292
|
|
|
|
|
d. |
Aggregated
information
|
-
83,614
-
660 pence per
share
|
|
e. |
Date of the
transaction |
2/2/2024 |
|
f. |
Place of the
transaction |
London Stock Exchange,
AIM |
4basebio (LSE:4BB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
4basebio (LSE:4BB)
Gráfica de Acción Histórica
De May 2023 a May 2024
